NASDAQ: VRCA - Verrica Pharmaceuticals Inc.

Rentabilidade por seis meses: -90.84%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Verrica Pharmaceuticals Inc.


Sobre a empresa Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.

mais detalhes
It is also developing VP-315, an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions, including basal cell carcinoma; and cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

IPO date 2018-06-15
ISIN US92511W1080
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.verrica.com
Цена ао 5.32
Alteração de preço por dia: +5.39% (0.649)
Alteração de preço por semana: -1.44% (0.694)
Alteração de preço por mês: -44.84% (1.24)
Alteração de preço em 3 meses: -59.53% (1.69)
Mudança de preço em seis meses: -90.84% (7.47)
Mudança de preço por ano: -90.66% (7.32)
Mudança de preço em 3 anos: -92.58% (9.22)
Mudança de preço em 5 anos: -95.78% (16.2)
Mudança de preço em 10 anos: 0% (0.684)
Mudança de preço desde o início do ano: -17.59% (0.83)

Subestimação

Nome Significado Nota
P/S 57.52 1
P/BV 14.91 1
P/E 0 0
EV/EBITDA -4.34 0
Total: 2.75

Eficiência

Nome Significado Nota
ROA, % -82.1 0
ROE, % -338.99 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.6985 10
Total: 7.8

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % -57.3 0
Rentabilidade Ebitda, % 106.63 10
Rentabilidade EPS, % 40.72 6
Total: 6.2

Instituições Volume Compartilhar, %
Perceptive Advisors LLC 5038983 11.98
Avoro Capital Advisors LLC 2954064 7.02
FMR, LLC 1504716 3.58
Vanguard Group Inc 1226858 2.92
Blackrock Inc. 1051050 2.5
Geode Capital Management, LLC 416790 0.99
State Street Corporation 382743 0.91
Caligan Partners, LP 259593 0.62
Northern Trust Corporation 187478 0.45
Boxer Capital, LLC 166955 0.4

ETFCompartilhar, %Rentabilidade para o ano, %Dividendos, %
Invesco Dorsey Wright SmallCap Momentum ETF 0.07518 33.91 0.61241
iShares Micro-Cap ETF 0.00867 17.09 1.54048
iShares Russell 2000 Growth ETF 0.0017 38.04 0.6026
ProShares UltraPro Russell2000 0.00074 89.82 1.47873
ProShares Hedge Replication ETF 0.00022 5.92 1.47892
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 3000 ETF 0 31.87 1.43817
0.0132.111.16



Supervisor Cargo Pagamento Ano de nascimento
Mr. Ted White President, CEO & Director 772.77k 1965 (60 anos)
Dr. Gary Goldenberg M.D. Chief Medical Officer 553.03k 1977 (48 anos)
Mr. P. Terence Kohler Chief Financial Officer N/A
Mr. Christopher G. Hayes Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel N/A 1964 (61 ano)
Mr. Eugene Scavola Executive Vice President of Technical Operations N/A
Dr. Bradley J. Catalone MBA, Ph.D. Head of Drug Development N/A

Endereço: United States, West Chester. PA, 44 West Gay Street - abrir no Google Maps, abrir mapas Yandex
Site: https://www.verrica.com